Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus teriflunomide in relapsing multiple sclerosis with open-label remibrutinib extension
CTR20221477Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in multiple sclerosis (MS), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started Sep 2022; status: active.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20221477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221477.